Vor Bio reports Q2 EPS (41c) vs (45c) last year

Cash, cash equivalents and marketable securities were $85.9 million as of June 30, 2024, which is projected to fund operations into the second half of 2025..”We are pleased with the progress we have made with enrollment of both the trem-cel + Mylotarg and VCAR33ALLO clinical trials during the quarter,” said Dr. Robert Ang, Vor Bio’s President and Chief Executive Officer. “Every year, thousands of patients with AML and MDS relapse post-transplant with no safe and effective treatment options. Our approach of shielded transplants may provide the first opportunity to